Pallas Health Review: The Best Disclosure Here, on a Quarterly Bill

The short version

Pallas Health sells sermorelin for $89 the first month, then $597 every twelve weeks — which it presents as "$199/mo average." The average is real arithmetic, but no month at $199 is purchasable: after the intro month the only cadence is a quarterly charge, and a twelve-week cycle recurs 4.33 times a year rather than four, so a year runs closer to $2,585 than to the $2,388 that "$199 a month" implies.

Everything else about this company is better than the category average, and some of it is the best on our ranking. Pallas names six dispensing pharmacies with phone numbers and domains, names its advising physician with an NPI you can verify yourself, names the corporation behind the platform, publishes the fifty states and DC it serves, and explains the difference between a 503A pharmacy and a 503B outsourcing facility correctly. Of the 33 providers we track, only a handful name a dispensing pharmacy at all, and none of them names six.

So: a company worth trusting with an unusually awkward billing shape. If you can absorb $597 at a time, it is a strong pick. If you want to try sermorelin for a month and stop, this is the wrong door.

The price, and the arithmetic behind it

The sermorelin page states it plainly, which we should credit before criticizing it:

> "$89 for your first month, then $597 every 12 weeks ($199/mo average). Auto-renews unless canceled — cancel anytime."

The plan price is stated to include your clinician, ongoing check-ins, care-team messaging and the medication itself, with no separate membership fee, free discreet shipping, and a full refund if a clinician decides treatment is not right for you. Shipping is quoted at about a week. It is FSA and HSA eligible, which is unusual here and worth real money to some readers.

Three things a reader should do with that number.

Multiply by 4.33, not 4. Twelve weeks is 84 days, so the charge recurs about 4.33 times in a 365-day year: $597 × 4.33 ≈ $2,585, plus the $89 first month in year one. "$199/mo average" divides one block by three months and stops there. The company is not hiding the block — it prints it in the same sentence — but the per-month figure is the one that gets remembered.

There is no monthly rung to fall back to. Several providers on this site publish a ladder where a month-to-month rate exists at the top and commitment buys a discount. Pallas publishes one cadence. The choice is the quarterly block or nothing.

"One price — never increases" sits beside a first month that increases. The claim is about the plan not being raised on you later, and read that way it is fair. Read as a shopper reads it, next to "$89 first month," it is doing more work than it should.

What it discloses, and why that is the story

Most of the sellers we track will not tell you who compounds the drug. Pallas publishes a compliance page — /clinical, dated on its face — that answers the questions a careful buyer actually has:

• •Six partner pharmacies, named, with phone numbers and domains: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills Pharmacy. It states that the pharmacy used depends on the medication, your shipping state and current capacity, and that state pharmacy license numbers are disclosed on request.
• •A correct explanation of compounding classes — 503A pharmacies licensed and inspected by state boards, 503B outsourcing facilities registered with and inspected by the FDA under cGMP. Most sites in this category either skip this or blur "FDA-registered" into "FDA-approved." Pallas does neither.
• •A named physician you can check: Dr Ana Lisa Carr, MD, board-certified in family, obesity and addiction medicine, listed as advising physician with NPI 1689841744 and an invitation to verify it in the NPPES registry.
• •A named corporate structure: the platform is operated by Brentmoor, Inc., which states that it does not employ medical providers, does not practice medicine and does not direct clinical decisions. Clinical care is delivered by Lion MD, a nationwide clinician network, through CareValidate, the clinical-operations platform that verifies licensure and coordinates dispensing.
• •Fifty states and the District of Columbia, listed individually.
• •A promise that you are given your treating clinician's name and license information before any prescription is issued, and that refills are not automatic — each renewal involves a clinician reviewing progress and tolerability.

There is one qualifier that matters, and it is the reason this section is praise rather than a recommendation on its own. That bench is shared. The same six pharmacies and the same Lion MD clinician network appear, in near-identical wording, on other brands running the CareValidate platform — Dr Carr is the same advising physician Synergy Rx names, and Care Bare Rx publishes the same pharmacy list. So this is genuine disclosure about the platform your prescription passes through, not independent evidence about Pallas specifically. Of the three, Pallas writes it up best.

The other qualifier is placement: none of this is on the sermorelin page. A reader who lands on the product, reads the price and clicks buy never meets it. It sits behind a footer link.

What it does not publish

No dose, strength or vial size. The page says "subcutaneous injection with clinician-personalized dosing" and leaves it there, so you cannot compare cost per milligram against a provider that does publish one.

No named pharmacy for your order in advance — six are named, but which one fills yours depends on your state and on capacity, and you find out later.

No FAQ or About page. Both /faq and /about return nothing; the compliance page carries what would normally live there.

To its credit, the sermorelin page does list contraindications in plain language — pregnancy or breastfeeding, active cancer, pituitary disease, untreated hypothyroidism, uncontrolled diabetes, heart failure — and answers "Is compounded sermorelin FDA-approved?" with a flat "No." That is more candor than most of this market manages, and it is the right answer⁴.

Does the treatment justify a quarterly commitment?

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone. It does not supply growth hormone; it prompts your own pituitary to release more of it², which is why it is dosed at night and why the best-supported effects are on sleep and the GH/IGF-1 axis rather than on the mirror. Nightly GHRH(1-29) raised GH and IGF-1 in healthy older men in a controlled study³; the wider literature on augmenting growth hormone in healthy adults finds small body-composition changes, no functional gain and a real side-effect rate⁵. Our evidence review grades each claim.

That evidence argues for finding out cheaply before committing. A twelve-week block is the opposite of finding out cheaply — though the $89 first month softens it, and the full refund if a clinician declines you removes the risk of paying for a "no."

Verdict

Take Pallas seriously if disclosure is what you care about. It names its pharmacies, its physician, its corporation and its states, it explains compounding classes correctly, and it tells you your clinician's license before it writes anything — a combination almost nothing else on this site offers. Then read the bill twice: $597 every twelve weeks, about 4.33 times a year, with no monthly option, and an advertised "$199/mo" you cannot actually buy a single month at.

If the quarterly charge is fine, this is one of the better-run desks here. If it is not, our price-sorted list shows who publishes a genuine month-to-month rate, and what they charge for it.